# US 2013/0259832 A1 · Combinations of Hepatitis C Virus Inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0259832 A1
- Document ID: US20130259832A1
- Status: Published application
- Kind: A1
- Application number: 13/792,898
- Filed: 2013-03-11
- Published: 2013-10-03
- Earliest claimed: 2009-10-12
- Applicants: Bristol-Myers Squibb Company
- Inventors: Julie A. Lemm; Stacey A. Voss; Min Gao; Susan E. Chaniewski; Amy K. Sheaffer; Fiona McPhee
- Web page: https://patentgrep.com/patent/US20130259832A1

## CPC

- A61K 38/06: Tripeptides
- A61K 31/4178: not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit Hepatitis C virus (HCV), compositions comprising such compounds, and methods for treating Hepatitis C using such combinations.

## Claims

### Claim 1

A composition comprising a therapeutically effective amount of a compound of formula (I)
or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of a compound of formula (II),
or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

### Claim 2 (depends on 1)

The composition of claim 1 further comprising one or two additional compounds having anti-HCV activity.

### Claim 3 (depends on 2)

The composition of claim 2 wherein at least one of the additional compounds is an interferon or a ribavirin.

### Claim 4 (depends on 3)

The composition of claim 3 wherein the interferon is selected from interferon alpha 2B, pegylated interferon alpha, consensus interferon, interferon alpha 2A, interferon lambda, pegylated interferon lambda, and lymphoblastoid interferon tau.

### Claim 5 (depends on 1)

A method of treating an HCV infection in a patient, comprising administering to the patient a therapeutically effective amount of a composition of claim 1.

### Claim 6 (depends on 1, 5)

The method of claim 5 further comprising administering one or two additional compound having anti-HCV activity prior to, after or simultaneously with the composition of claim 1.

### Claim 7 (depends on 6)

The method of claim 6 wherein at least one of the additional compounds is an interferon or a ribavirin.

### Claim 8 (depends on 7)

The method of claim 7 wherein the interferon is selected from interferon alpha 2B, pegylated interferon alpha, consensus interferon, interferon alpha 2A, interferon lambda, pegylated interferon lambda, and lymphoblastoid interferon tau.
